Epitomics Signs Contract to Develop Antibodies for NCI's Proteomics Initiative

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.